Navigation Links
Study Shows Leconotide, an Investigative Calcium Channel Blocker, Has Potential as a Selective, Efficacious, Non-Opioid Pain Treatment
Date:1/28/2009

HONOLULU, Jan. 28 /PRNewswire/ -- Results of a pre-clinical study of leconotide, an investigative calcium channel blocker, shows it has the potential to be safe, selective, and efficacious as a new non-opioid treatment for pain relief. It also holds promise in multiple drug delivery options including nasal spray, transdermal patch, and pills. Data were presented today at the American Academy of Pain Medicine's 25th Annual Meeting.

In the study, leconotide, when given intravenously to treat neuropathic pain, was selective for calcium channels involved with pain and it did not act on other calcium channels to cause side effects, as has been seen in studies of other calcium channel blockers used for treating pain. It was efficacious alone, but more so when it was given in combination with a potassium channel opener (flupirtine). The study also showed that leconotide, unlike currently available treatments of this type, does not have to be administered directly into the spinal fluid to achieve pain relief, and so could have the potential to be delivered via nasal spray, transdermal patch, or pill.

Leconotide was also compared with ziconotide, an established calcium channel blocker, which was given intravenously with and without flupirtine. In this study, ziconotide was not an effective pain reliever, given alone or in combination with flupirtine.

"There is a tremendous need for non-opioid treatments for neuropathic pain, so the results of this study are exciting for researchers in the field of pain medicine, doctors whom treat pain, and patients who suffer or are under-treated because of the abuse potential and side effects associated with opioid treatments," said Colin Goodchild, PhD, and director of the Centre for Pain Research and Palliative Care, Monash Institute of Medical Research.

To determine the efficacy and side effect profile of leconotide, researchers at Monash Institute of Medical Research studied 322 rodents in a model of induced diabetic neuropathy and hyperalgesia, or extreme sensitivity to pain. Roughly one-third of the rodents were given injections of two calcium channel blockers (leconotide or ziconotide) alone and in combination with flupirtine (a potassium channel opener). Roughly another third were given a range of doses up to the maximum that would not induce sedation. About half of the rodent's pain was reduced in the group with leconotide compared to less than 1 percent when ziconotide was given alone.

Leconotide in combination with flupirtine increased the reduction of pain, demonstrating selectivity -- it did not act on the channels that cause the side effects seen with ziconotide treatment.

Leconotide is derived from marine hunting cone snail Conus Catus.

About Calcium Channel Blockers

Every cell in the body is enclosed by a membrane which acts as a barrier controlling the flow of chemicals into and out of the cell. Channels through the membrane control the passage of substances into and out of the cell. Some are specialized for the flow of chemical ions such as sodium, potassium and calcium. The amount of ions of each species passing through those channels controls many functions of the cell such as force of contraction of a muscle cell in the heart or blood vessels or rate of electrical firing or production of chemical messengers in nerve cells. Calcium antagonists block calcium channels. There are many types of calcium channels. Medicines can be selective to bind just with one type (e.g. heart and blood vessels to lower blood pressure). Calcium channels in nerve cells are involved with many functions (e.g., pain, memory and control of consciousness). The goal is to find a calcium antagonist that only affects the channels involved with pain to cause pain relief without side effects like feeling sleepy.

    Poster Session Information (Poster 181)
    Begins: 3:30 PM (Hawaiian Time), Wednesday, January 28, 2009
    Ends:  10:00 AM (Hawaiian Time), Thursday, January 29, 2009
    Location:  Coral Ballroom Foyer, Hilton Hawaiian Village

About the AAPM

For more than 25 years, the American Academy of Pain Medicine (AAPM) has been the medical specialty society representing more than 2,200 physicians practicing in the field of pain medicine. The Academy is involved in education, training, advocacy and research in the specialty of pain medicine. Information is available on the practice of pain medicine at http://www.painmed.org.


'/>"/>
SOURCE American Academy of Pain Medicine
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Study of Cannabinoid Medicine for Pain Found Patients Got High, but Effects Not Related to Pain Relief
2. Study Shows No Standardized Approach to Epidural Steroid Injections for Back Pain
3. ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
4. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
5. Thomson Reuters Study Finds Sharp Increase in Use of Sleep Medications by Young Adults
6. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
7. Study Shows How Defective DNA Repair Triggers Two Neurological Diseases
8. New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
9. New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors
10. VA-NIH Study Offers Hope for Parkinsons Patients
11. Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that Frost & ... Innovation Award for Its fibromyalgia pain management device. The ... market research by Frost & Sullivan,s industry experts. ... product, the AVACEN 100, offers a safe and effective solution ... ...
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
Breaking Medicine Technology:
(Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains ... possible to save lost souls in the Philippines. “The Journey: From the Mountains to ... dedicated teacher of the Bible. She has taught all ages and currently teaches a ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
Breaking Medicine News(10 mins):